BAVIS_1170x120_1-20

Sandoz U.S. portfolio

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

Novartis to sell portions of Sandoz U.S. portfolio to Aurobindo

BASEL— Novartis today announced it has agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billion of potential earn-outs. This transaction supports the Sandoz strategy of focusing on complex